Capsugel's Scintigraphic In Vivo Study of DRcaps Capsules Tracks Successful Delayed Release
Capsugel, a global leader in innovative dosage forms and solutions for the healthcare industry, has announced that the results of its 2013 scintigraphic in vivo study of its DRcaps capsules definitively documents that the specially formulated acid-resistant hydroxypropyl methylcellulose (HPMC) capsules are an “excellent choice” for delayed delivery of acid-sensitive ingredients such as probiotics and enzymes.
Data and images empirically demonstrate the capsules’ effective protection from early activation caused by stomach acids and, for a majority of study subjects, complete release in intestines where products such as probiotics and enzymes work best. More specifically, the capsules began release in a mean time of 52 min after ingestion and completely released the ingredients in a mean time of 72 min after ingestion.
“The results from this human clinical study provide scientific evidence of DRcaps capsules’ acid-resistant and delayed-release performance to give confidence that DRcaps capsules are an excellent choice for delivery of acid-sensitive ingredients,” said Dr Keith Hutchison, Senior Vice President of R&D at Capsugel.
The study was designed to investigate the in vivo behavior of DRcaps using a scintigraphic method to assess the gastrointestinal transit and release of the contents from capsules based on the images obtained. Gamma scintigraphy is an established technique in which a radio label is swallowed and the disposition in the gut is photographed externally over time.
The scintigraphic study revealed that the capsules actually began releasing at 52 min when they were about to leave the stomach. “That is 45 min later than an immediate release capsule and means that the contents of the capsules would often be released in the intestines — where probiotics and enzyme ingredients are most effective,” Dr Hutchison elaborated.
DRcaps capsules are designed with unique polymer properties to slow down capsule opening after swallowing without adding synthetic chemicals, solvents or other coating ingredients. “The special release properties built into the capsules provide the choice of a vegetarian product for fast product launches, and still provide acid-protection and delayed release,” Dr Hutchison concluded.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance